Advertisement

Effects of cilostazol and renin-angiotensin system (RAS) blockers on the renal disease progression of Korean patients: a retrospective cohort study

  • 226 Accesses

Abstract

Background Decline in estimated glomerular filtration rate (eGFR) is an important surrogate marker for the assessment of renal function. Addition of a second agent to angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) treatment may improve current therapeutic strategies aimed at suppressing renal disease progression. Objective To determine the effect of cilostazol in combination with ACEI or ARB treatment on the decline in eGFR. Setting A tertiary hospital in Korea. Method In an observational cohort study, we analyzed 5505 patients who were prescribed ACEI or ARB and cilostazol or other antiplatelet agents. Main outcome measure The primary outcome assessed was worsening of renal function defined as a 30% decline in eGFR per year. The secondary outcomes included commencement of dialysis, renal transplantation, death, myocardial infarction, and ischemic stroke. Results Following propensity score matching, eGFR decreased over time in the majority of patients, but the decline was less in patients in the cilostazol treated (CT) group of stage 1–2 category compared to the cilostazol untreated (CU) group (OR 0.80; 95% CI 0.66–0.98). In the subgroup analysis, the strongest effect in slowing eGFR decline was observed in CT patients at a high risk of diabetes (OR 0.782; 95% CI 0.615–0.993) and the elderly (OR 0.693; 95% CI 0.504–0.953) in the stage 1–2 category. No significant increase in cardiovascular risk was observed between the CT and CU groups. Conclusion Treatment with cilostazol plus ACEI or ARB was observed to prevent worsening of renal progression in patients in the stages 1–2.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

Fig. 1
Fig. 2

References

  1. 1.

    Park JI, Baek H, Jung HH. Prevalence of chronic kidney disease in Korea: the Korean National Health and Nutritional Examination Survey 2011–2013. J Korean Med Sci. 2016;31(6):915–23.

  2. 2.

    Hazzan AD, Halinski C, Agoritsas S, Fishbane S, DeVita MV. Epidemiology and challenges to the management of advanced CKD. Adv Chronic Kidney Dis. 2016;23(4):217–21.

  3. 3.

    Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2016;389(10075):1238–52.

  4. 4.

    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. NEJM. 2004;351(13):1296–305.

  5. 5.

    Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl. 2005;99:S57–65.

  6. 6.

    Stefoni S, Cianciolo G, Baraldi O, Iorio M, Angelini ML. Emerging drugs for chronic kidney disease. Expert Opin Emerg Drugs. 2014;19(2):183–99.

  7. 7.

    Molnar MZ, Kalantar-Zadeh K, Lott EH, Lu JL, Malakauskas SM, Ma JZ, et al. Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J Am Coll Cardiol. 2014;63(7):650–8.

  8. 8.

    MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD, et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis. 2006;48(1):8–20.

  9. 9.

    Egido J, Fernandez-Fernandez B, Ortiz A, Mas S, Gómez-Guerrero C. Standard and novel therapeutic approaches to diabetic nephropathy. Port J Nephrol Hypertens. 2015;29(2):101–7.

  10. 10.

    Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. NEJM. 2013;369(20):1892–903.

  11. 11.

    Zou Y, Hu C, Ye W, Fan L, Xu L, Zhang A, et al. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy after drug-eluting stent implantation in coronary arteries: a meta-analysis of randomized controlled trials. Thromb Res. 2015;136(5):870–7.

  12. 12.

    Ragab D, Abdallah DM, El-Abhar HS. Cilostazol renoprotective effect: modulation of PPAR-gamma, NGAL, KIM-1 and IL-18 underlies its novel effect in a model of ischemia-reperfusion. PLoS ONE. 2014;9(5):e95313.

  13. 13.

    Wang X, Yan L, Chen W, Xu L, Zhang X. The renal protective effects of cilostazol on suppressing pathogenic thrombospondin-1 and transforming growth factor-beta expression in streptozotocin-induced diabetic rats. J Int Med Res. 2009;37(1):145–53.

  14. 14.

    Tang WH, Lin FH, Lee CH, Kuo FC, Hsieh CH, Hsiao FC, et al. Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. Endocrine. 2014;45(2):293–301.

  15. 15.

    International K. Is a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials? Int Soc Nephrol. 2014;85:723–7.

  16. 16.

    Beddhu S, Samore MH, Roberts MS, Stoddard GJ, Pappas LM, Cheung AK, et al. Creatinine production, nutrition, and glomerular filtration rate estimation. J Am Soc Nephrol. 2003;14(4):1000–5.

  17. 17.

    Cartet-Farnier E, Goutelle-Audibert L, Maire P, De la Gastine B, Goutelle S. Implications of using the MDRD or CKD-EPI equation instead of the Cockcroft-Gault equation for estimating renal function and drug dosage adjustment in elderly patients. Fundam Clin Pharmacol. 2017;31(1):110–9.

  18. 18.

    International K. Is a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials? Int Soc Nephrol. 2014;85:723–7.

  19. 19.

    Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–72.

  20. 20.

    KDIGO. clinical practice guideline for the evaluation and management of chronic kidney diseas. Kidney Int Suppl. 2012;2013(3):136–50.

  21. 21.

    Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–53.

  22. 22.

    Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ. 2013;346:f360.

  23. 23.

    Jiao XM, Jiao XJ, Zhang XG, Xu XP, Wu JX, Yao L, et al. Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy. Chin Med J. 2013;126(22):4395–6.

  24. 24.

    Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke J Cereb Circ. 1997;28(3):557–63.

  25. 25.

    Khan SS, Kazmi WH, Abichandani R, Tighiouart H, Pereira BJ, Kausz AT, et al. Health care utilization among patients with chronic kidney disease. Kidney Int. 2002;62(1):229–36.

  26. 26.

    Earlier endpoints proposed for chronic kidney disease trials. Nephrol News. 2012. https://www.kidney.org/news/newsroom/nr/Earlier-Endpoints-Proposed-for-Clinical-Trials-in-CKD. Accessed 30 July 2017.

  27. 27.

    Schnaper HW, Furth SL, Yao LP. Defining new surrogate markers for CKD progression. Pediatr Nephrol. 2015;30(2):193–8.

  28. 28.

    Wang F, Li M, Cheng L, Zhang T, Hu J, Cao M, et al. Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats. Life Sci. 2008;83(25–26):828–35.

  29. 29.

    Agrawal NK, Maiti R, Dash D, Pandey BL. Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. Pharmacol Res. 2007;56(2):118–23.

  30. 30.

    Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005;6(4):3–11.

  31. 31.

    Suzuki K, Uchida K, Nakanishi N, Hattori Y. Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes. Am J Hypertens. 2008;21(4):451–7.

  32. 32.

    Service NHI. Koean diabetes fact sheet. Seoul: Korean Diabetes Association; 2015.

  33. 33.

    Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2013;2:CD008834.

  34. 34.

    Saran RDD, Wolfe RA, Gillespie B, Held PJ, Young EW. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2002;40(6):1255–63.

  35. 35.

    Ghorbani A, Aalamshah M, Shahbazian H, Ehsanpour A, Aref A. Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian J Nephrol. 2009;19(2):57–61.

  36. 36.

    Chang CC, Liou HH, Wu CL, Chang CB, Chang YJ, Chiu PF, et al. Warfarin slows deterioration of renal function in elderly patients with chronic kidney disease and atrial fibrillation. Clin Interv Aging. 2013;8:523–9.

Download references

Acknowledgements

This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (No. 2013M3A9B5075838).

Funding

None

Conflicts of interest

The authors declare that they have no conflicts of interest.

Author information

Correspondence to Sukhyang Lee.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Noh, Y., Lee, J., Shin, S. et al. Effects of cilostazol and renin-angiotensin system (RAS) blockers on the renal disease progression of Korean patients: a retrospective cohort study. Int J Clin Pharm 40, 160–168 (2018) doi:10.1007/s11096-017-0578-4

Download citation

Keywords

  • Angiotensin receptor blocker
  • Angiotensin-converting-enzyme inhibitors
  • Chronic kidney disease
  • Cilostazol
  • Glomerular filtration rate (GFR)
  • Renal disease progression
  • South Korea